Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study (NCT06033833)
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
🩺 Plain-English Summary (8th-Grade Level)
This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks. The number of visits will be 18.
Who can join: Review the eligibility criteria below.
Location: Bensch Research Associates- Site Number : 8400004 — Stockton, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (68 Sites)
Showing the first 25 of 68 sites.
- Bensch Research Associates- Site Number : 8400004 — Stockton, California
- Helix Biomedics- Site Number : 8400029 — Boynton Beach, Florida
- Savin Medical Group - Miami Lakes- Site Number : 8400015 — Miami Lakes, Florida
- Pines Care Research Center- Site Number : 8400028 — Pembroke Pines, Florida
- Treasure Valley Medical Research- Site Number : 8400031 — Boise, Idaho
- Johns Hopkins Bayview Medical Center- Site Number : 8400012 — Baltimore, Maryland
- OK Clinical Research- Site Number : 8400001 — Edmond, Oklahoma
- South Texas Medical Research Institute - TTS Research- Site Number : 8400011 — Boerne, Texas
- Investigational Site Number : 0320008 — La Plata, Buenos Aires
- Investigational Site Number : 0320005 — Rosario, Santa Fe Province
- Investigational Site Number : 0320006 — Rosario, Santa Fe Province
- Investigational Site Number : 0320007 — Rosario, Santa Fe Province
- Investigational Site Number : 0320004 — Buenos Aires,
- Investigational Site Number : 0320003 — Buenos Aires,
- Investigational Site Number : 0320001 — Buenos Aires,
- Investigational Site Number : 0320002 — Buenos Aires,
- Investigational Site Number : 0320009 — Buenos Aires,
- Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 0760002 — Vitória, Espírito Santo
- Associacao Proar- Site Number : 0760004 — Salvador, Estado de Bahia
- Instituto Méderi de Pesquisa e Saúde- Site Number : 0760001 — Passo Fundo, Rio Grande do Sul
- Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760007 — Porto Alegre, Rio Grande do Sul
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006 — Porto Alegre, Rio Grande do Sul
- Clinica de Alergia Martti Antila- Site Number : 0760003 — Sorocaba, São Paulo
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760008 — São Paulo,
- Investigational Site Number : 1240008 — Ottawa, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype — Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma — San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study — La Jolla, California
Explore by condition: All Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.